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miR-675The oncofetal H19 gene transcribes a long non-coding RNA(lncRNA) that is essential for tumor growth. Here we
found that numerous established inducers of epithelial tomesenchymal transition(EMT) also induced H19/miR-
675 expression. Both TGF-β and hypoxia concomitantly induced H19 and miR-675 with the induction of EMT
markers. We identiﬁed the PI3K/AKT pathway mediating the inductions of Slug, H19 RNA and miR-675 in re-
sponse to TGF-β treatment, while Slug induction dependedonH19RNA. In the EMT inducedmultidrug resistance
model, H19 level was also induced. In a mouse breast cancer model, H19 expression was tightly correlated with
metastatic potential. In patients, we detected high H19 expression in all commonmetastatic sites tested, regard-
less of tumor primary origin. H19 RNA suppressed the expression of E-cadherin protein. H19 up-regulated Slug
expression concomitant with the suppression of E-cadherin protein through a mechanism that involved miR-
675. Slug also up-regulated H19 expression and activated its promoter. Altogether, these results may support
the existence of a positive feedback loop between Slug and H19/miR-675, that regulates E-cadherin expression.
H19 RNAenhanced the invasive potential of cancer cells in vitro and enhanced tumormetastasis in vivo. Addition-
ally, H19 knockdown attenuated the scattering and tumorigenic effects of HGF/SF. Our results present novel
mechanistic insights into a critical role for H19 RNA in tumor progression and indicate a previously unknown
link between H19/miR-675, Slug and E-cadherin in the regulation of cancer cell EMT programs.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Delineating the molecular mechanisms underlying cancer recur-
rence and metastasis is vitally important. Tumor metastasis is the
primary cause ofmortality formost cancer patients, accounting approx-
imately for 90% of all cancer deaths. One of the major mechanisms that
mediates metastasis is EMT [1]. EMT is a prerequisite for invasion and
dissemination of carcinoma cells [2]. Although EMT has been demon-
strated in most cancer types, it has been particularly well studied in
pancreatic cancer. EMT and dissemination have been shown to precede
pancreatic tumor formation [3], and expression of EMTmarkers in pan-
creatic patient biopsies correlate with poor survival [4]. Pancreatic can-
cer EMT is triggered by hypoxia and inﬂammation and is involved in
cancer cell stemness and multidrug resistance [5]. Consequently it is
critical to ﬁnd the molecular mediators of EMT, which would provide
new targets for intervention in the process of metastatic recurrence of
tumors.972 2 548 6550.
uk).H19 RNA is frequently over-expressed in the majority of human
cancers, sometimes via loss of imprinting. Although its role in tumor-
igenesis is debated, the prevailing view is that H19 behaves like an
oncogene [6,7]. Recent efforts to better characterize the H19 locus
have revealed that it houses several overlapping transcriptions on
the two DNA strands that can produce different transcriptional prod-
ucts [8]. In addition to H19 RNA itself, this locus also produces a
micro-RNA called miR-675 [9], an antisense protein coding tran-
script called H19 opposite tumor suppressor (HOTS) [10], and a
long intergenic antisense transcript called 91H [11]. Moreover, vari-
ous splice variants have been reported [12]. The variety of products
produced from the H19 gene locusmay account for the discrepancies
when dealing with H19 oncogenic effects. Moreover, H19 tumori-
genic activity may depend on p53 status as we previously proposed
[13].
In recent years, it has become increasingly clear that H19 RNA is
essential for human tumor growth and that the H19 gene is regulated
by a complex interplay of factors whose malfunctioning plays a critical
role in tumorigenesis. In our recent studies we identiﬁed hypoxia as a
key trigger enhancing the expression of the H19 gene, andwe also char-
acterized the major transcriptional interplay between its positive and
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have been identiﬁed. A molecular mechanism integrating H19, p53
and hypoxia-inducible factor 1-α (HIF1-α) with the hypoxic stress re-
sponse has been uncovered in which p53 suppression of H19 may, at
least in part, involve interference with HIF1-α activity [6,13].
H19 is one of the transcriptional targets of c-Myc which strongly
induces the expression of the maternal H19 allele and binds directly
to un-methylated E-boxes close to the imprinting control region to
potentiate tumorigenesis [14]. Given the strong association between
H19 and c-Myc expressions, the essential role of H19 in transformation
suggests that c-Myc-inducedH19 expression contributes to tumor etiol-
ogy and the strong oncogenic behavior of c-Myc.
Further supports for the involvement of H19 RNA in cell cycle pro-
gression have been provided by our group and others. We previously
have shown that in serum starved conditions over-expression of the
H19 gene can override cell cycle growth arrest and induce cells to
enter the S phase, an effect which is accompanied by suppression
of the expression level of the cyclin-dependent kinase inhibitor
p57Kip2 [15]. This was supported by the ﬁndings of another group
that H19 RNA is important for entry into the S-phase after recovery
from serum starvation via E2F binding to its promoter [16]. H19 is
suppressed by the tumor suppressor p53 [13,17]. Furthermore,
miR-675, which is excised from exon one of H19, targets retinoblas-
toma tumor suppressor gene product [18]. All of these observations
place the H19 locus at the core of cell cycle control, especially in the
transition from G1 to S phase.
Numerous observations support the involvement of H19 RNA in the
metastatic cascade, however, both functional and mechanistic data are
lacking. The aimof thepresent study is to explore this issue. H19 expres-
sion was studied in biopsies selected to represent common metastatic
sites and in a well established syngeneic mouse model of mammary
cancer composed of a panel of cancer cell line variants each can perform
deﬁnitive step in the metastatic cascade. We then studied H19's in-
volvement in EMT utilizing well-established effectors and explored
the molecular mechanism mediating H19 modulation using speciﬁc
chemical inhibitor of signaling pathway and H19 over-expression
approaches. These studies were followed by functional analyses using
H19 over-expression and knockdown approaches. Our results present-
ed here demonstrate that H19/miR-675 axis promotes tumor metasta-
sis at least being part of the EMT process.2. Materials and methods
2.1. Ethical statement
All procedures and the care given to the animals were approved by
the local committee for animal welfare. Animals were kept in the
Hebrew University's animal facility with water and food ad libitum. All
experimental research on animals followed internationally recognized
guidelines.2.2. Cell culture conditions and treatments
All the cells used in this study were grown in Dulbecco's modiﬁed
Eagle's medium (DMEM-F12) containing 10% fetal bovine serum. For
hypoxic treatment, cells were grown in 1.2% O2, 5% CO2 for the indicated
time before RNA and protein extractions.
For experiments involving TGF-β stimulation, Hep3B and UMUC3
cells were treated with 2 ng/ml TGF-β for 48 h and 24 h respectively
before RNA extraction. When PI3K/AKT inhibitor (LY294002)
was used, Hep3B cells were pre-treated with the inhibitor at a
concentration of 20 μM for 1 h prior to TGF-β stimulation for 48 h.
For experiment involving siRNAs, it is performed as previously
described [6,13].2.3. Reverse transcription for microRNA detection
Hsa-mir-675 and RNU48miRNAs were reverse transcribed with the
TaqMan miRNA reverse transcription kit (Applied Biosystems, Forster
city, CA). 10 ng of total RNA and 3 μl of microRNA speciﬁc primers
were used in 15 μL RT reaction buffer according to the manufacturer's
instructions (Applied Biosystems).
2.4. Real-time quantitative PCR
H19, Snail and Slug expression levelsweremeasured using real-time
quantitative PCR (QPCR). The RNA levelsweremeasured relative to beta
actin (ACTB). PCR reactions were carried out in triplicates using FAM as
the ﬂuorescent detection dye and using the real-time PCR system
Mx3000P (Stratagene, La Jolla, CA). The H19, Snail and Slug
TaqMan reactions were optimized and shown to have an equal am-
pliﬁcation efﬁciency as the beta actin. 2 μl of each cDNA was ampli-
ﬁed in 20 μl volume PCR reaction containing the human
H19 forward primer TGCTGCACTTTACAACCACTG; H19 reverse
primer ATGGTGTCTTTGATGTTGGGC; and the TaqMan probe
TCGGCTCTGGAAGGTGAAGCTAGAGGA which spans the junction of
exons 4 and 5, thus providing speciﬁcity to the RNA and not the
genomic DNA [45]. For mouse H19, PCR reaction contained the
forward primer CGGCGACGGAGCAGTGAT; reverse primer ACCTGT-
CATCCTCGCCTTCA; and the TaqMan probe TGGAGACTAGGCCAG-
GTCTCCAGCA. Primers and TaqMan probes for Snail and Slug were
as follows: Snail: ACCACTATGCCGCGCTCTT; and GGTCGTAGGG-
CTGCTGGAA; Slug: TGTTGCAGTGAGGGCAAGAA; and GACCCTG-
GTTGCTTCAAGGA′; the TaqMan probe for Snail: TCGTCAGGAA-
GCCCTCCGACCC; and Slug: AGGCTTCTCCCCCGTGTGAGTTCTAATG. Each
primer was placed in a different exon to avoid ampliﬁcation of contaminat-
ing genomic DNA [46]. For human ACTB the forward primer was
GACAGGATGCAGAAGGAGATCACTG; the reverse primer CGCCGATCCACA-
CGGAGTACTT; and TaqManprobe ATGAAGATCAAGATCATTGCTCCTCCT.
Whereas for mouse (Actb), the forward primer was GACAGGA-
TGCAGAAGGAGATTACTG; reverse primer CCACCGATCCACACAGAGT-
ACTT; and TaqMan probe CCATGAAGATCAAGATCATTGCTCCTCCT. All
the DNA sequences listed above are written in 5' to 3' direction. 1× AB-
solute Blue QPCR low ROX mix (ABgene) was used with the following
cycling parameters: 95 °C for 15 min, followed by 40 cycles of 95 °C
for 15 s and 60 °C for 1 min. All QPCR runs included a 6-points standard
curve of known dilution; the efﬁciency of PCR was calculated from the
slope of the standard curve and was within the range of 90–110%.
For miRNA, hsa-mir-675 was quantiﬁed utilizing TaqMan speciﬁc
microRNA assay kit (Applied Bioystems). The expression of small
nucleolar RNA RNU48 served as an endogenous control for normaliza-
tion. 1.33 μl of the 1:15 dilution from the RT reaction and TaqMan Uni-
versal PCR Master Mix, No AmpErase UNG (Applied Biosystems) were
used in 20 μl QPCR reaction mix. The reaction was initiated at 95 °C
for 10 min, followed by 40 cycles of 95 °C for 15 s, and 60 °C for 1 min.
2.5. Patient biopsies and LNA in situ hybridization
In situ hybridization (ISH) for H19 was done with speciﬁc 5′ end
digoxigenin (DIG) labeled locked nucleic acid based probe (LNA),
(Exiqon Inc, MA). The LNA-modiﬁed probes are used to enhance
the detection, achieve superior sensitivity and improve speciﬁcity
of the ISH reaction. Parafﬁn sections cut from archival material (par-
afﬁn blocks) selected to represent metastasis to common sites were
subjected to ISH for H19. Approximately 5 μm thick sections from tis-
sue blocks were deparafﬁnized in xylene and rehydrated in descend-
ing grades of alcohol, followed by treatment with 0.1% Triton-100/
PBS. The slides were then washed with PBS (pH 7.5) and perme-
abilized by being incubated in 10 μg/ml proteinase K (Ambion) for
25 min at 37 °C. Slides were rinsed in PBS, and then reﬁxed for
5 min in 4% paraformaldehyde/PBS. Thereafter, they were rinsed in
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in 0.1 M triethanolamine (Sigma) at pH 8.0, rinsed in PBS, then
RNase-free water, dehydrated, and air dried.
The hybridization buffer contained 50% deionized formamide, 0.3 M
NaCl, 20mMTris–HCl (pH 7.4), 5 mMEDTA, 10mMNaH2PO4 (pH 8.0),
10% dextran sulphate, 1× Denhardt's solution, and 0.5 μg/ml yeast
tRNA. Each slide was covered with 30 μl of the hybridization solution
containingDIG labeled LNAprobes. The negative controls either omitted
the probe or used scrambled probe. Human beta-actin DIG labelled LNA
probe was used as a positive control.
Slides were covered with siliconized coverslips and hybridization
was performed at 52–54 °C for at least 14 h in a humidity chamber.
After hybridization, coverslips were gently ﬂoated off in 2× SSPE +
0.1% SDS solution for 5 min. Slides were washed with 0.1× SSPE +
0.1% SDS for 10min at 55 °C followed by rinsing twice in 2× SSPE, equil-
ibrated in buffer 1 (100 mM Tris–HCl and 150 mM NaCl, pH 7.5). This
was followed by blocking with 2% sheep serum for 30 min (to avoid
non-speciﬁc crossreactions of the primary antibody), after that slides
were incubated with 1:2,000 anti-DIG-AP Fab fragments antibody
(Roche Applied Sciences, Indianapolis, IN) in a humidiﬁed chamber for
3 h at room temperature, followed by two washes in buffer 1. Slides
were equilibrated in buffer 2 (100 mM Tris–HCl, 100 mM NaCl, and 50
mM MgCl2, pH 9.5) for 10 min. The color reaction was carried out by
incubation in 5-bromo-4-chloro-3-indolyl phosphate (BCIP)/nitro
blue tetrazolium (NBT) color solution (Roche Applied Sciences,
Indianapolis, IN) with 1 mM levamisole for 12–16 h in a humidity
chamber and allowed to develop in the dark at room temperature. The
reaction was stopped in buffer 3 (10 mM Tris–HCl and 1 mM EDTA,
pH 7.4) for a few minutes. Finally, the sections were counterstained
with 3% Giemsa stain and quickly dehydrated. The slides were then
mounted and observed under Olympus B×40 microscope.
2.6. Western blot analyses
Cell proteinwas extracted by TRI reagent solution (Sigma) and load-
ed to 4–12% polyacrylamide precast gels. Gels were blotted on PVDF
sheets and their residual content was analyzed for visually estimated
quantiﬁcation by Coomassie staining. The blots were subjected to
the following antibodies: goat anti N-Cadherin 1:1000 (Santa Cruz);
mouse anti E-Cadherin, 1:1000 (Abcam); mouse anti GAPDH 1:2500
(Santa Cruz). Secondary horseradish-peroxidase antibodies (anti-mouse
10−4, otherwise: 1/30,000) were from Jackson. SuperSignal West Pico
Chemiluminescent Substrate (Pierce) was used as a substrate.
2.7. In vitro invasion assay
To assess the effect of H19 RNA on the metastatic potential of cells
in vitro, we used the non-metastatic hepatocellular carcinoma Hep3B
cell line and BD biocoat matrigel invasion chambers (BD Biosciences) ac-
cording to the manufacturer instructions. Brieﬂy 50,000 Hep3B cells and
its H19 over-expression variant were plated seperately in serum free
medium in invasion chambers which contained an 8 micron pore size
PETmembranewith a thin layer ofmatrigel basementmembranematrix.
As a chemo-attractant, the same medium with 10% fetal calf serum was
placed in the wells which contained the invasion chambers, and the
cells were incubated for 18 h. For measurement of cell invasion, non-
invading cells were removed from the upper surface of the membrane
by ﬁrm scrubbing using cotton swabs. Cells were then ﬁxed bymethanol
treatment, and stainedwithGiemza. Excess stainwaswashed awayusing
DDWand invading cells were quantiﬁed using Image Pro-Plus. Each type
of cell was plated in triplicate, and the experiment was performed twice.
2.8. Generation of cell lines ectopically expressing H19 RNA
H358, Hep3B and Panc-1 cells were transfected with an expression
vector inwhich theH19 genewas under the constitutive transcriptionalcontrol of the CMVpromoter, producing cellswith stable over-expression
of H19 RNA. Cells were transfected with the same vector backbone with
an empty transcriptional unit as control.
24 h before transfection, cells were plated into 6well plates at a den-
sity of 1 × 105 cells/per well in antibiotic free medium. Transfections
were carried out using lipofectamine 2000 and 2 μg plasmid per well
as previously described [13]. 48 h after transfection, cells were diluted
and divided into new culture dishes. Cells were selected after being
grown 15 days in a medium containing 500 μg/ml G418 sulfate antibi-
otic (Gibco-BRL).
2.9. Anchorage-independent growth assay
Lung cancer cell lines A549 and H358 were each seeded in 60 mm
plates, and transfected in duplicates with siRNA duplexes targeting
H19 RNA, with an unrelated control siRNA targeting the luciferase
(siLUC), or left to grow with no treatment (NT). 12 h post transfection,
one plate of each duplicate were exposed to hypoxic conditions while
the others remained in normoxia for another 24 h. Cells were washed
with PBS, trypsinized and counted. 5 × 103 cells from each 60 mm
plate were then seeded in 6-well plates containing 0.35% top and 0.8%
base high DNA grade agarose, in two sets of triplicates. In one set, cells
were left to grow in normal growth conditions with 1 ml medium
renewed every 3–4 days. In the other set, growth medium was supple-
mented with HGF at ﬁnal concentration of 20ng/ml for A549 and
40 ng/ml, for H358. 4 weeks (A549 cells) and 6 weeks (H358 cells)
post seeding, colonies were dyed with 0.05% crystal violet and counted
under the lightmicroscope. Colony size and shapewere also noted. Col-
ony counting procedure: a transparent paper was cut to be at the
same shape and size as one of the wells. It was divided into 59
small (0.4 × 0.4 cm) squares. Colonies in 8 random squares were
counted (for this count standard deviation did not exceed a
maximum value of ±3 for wells that were not treated with HGF
and ±5 for those that were). The mean value of this count was
then multiplied by 59 to give the ﬁnal absolute number of colonies
per well. The standard errors presented are for the mean of three
triplicates.
2.10. In vivo experiments
To check the effect of H19 RNA onmetastatic potential of cells in vivo,
we used the human lung carcinoma H358 cell line. We generated an H19
over-expressing variant with its control being cells transfected with an
empty plasmid as described above. Conﬂuent cells were trypsinized to a
single cell suspension and resuspended in PBS. 1 × 106 cells (in 150 μl
volume) were intravenously injected into the tail vein of 6–8 weeks\
old female CD1 nude mice. 28 days post injections, mice were sacriﬁced
and their lungs, brains and livers were examined for both macro and
micro metastasis.
2.11. Semi-quantitative RT-PCR analyses
Reverse transcription was performed as previously described [13].
Details of the PCR conditions and the PCR primer sequences are avail-
able upon request.
2.12. Plasmid design
The full length H19 gene driven by the CMV promoter was designed
by GeneArt and fully sequenced. The H19 cDNAwas cloned into pCMV-
Skript. The control vectorwas designedwithout theH19 insert. The Slug
expression plasmid (19293) was from Addgene [30]. For the generation
of the expression vector CMV-Slug, Slug insert present in the vector
19293was digestedwith BamH1, EcoR1 restriction enzymes and cloned
into the backbone pCMV-Skript vector. The control vector was designed
without the Slug insert.
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All data are expressed as mean ± standard deviation. The differ-
ences between groups were analyzed using student's t test. The differ-
ences were deemed statistically signiﬁcant at p b 0.05.
3. Results
3.1. Classical inducers of EMT modulate H19 gene expression
Several factors have been shown to induce the EMT process. Themost
established and relatively well studied effectors are the transforming
growth factor beta (TGF-β), hypoxia, hepatocyte growth factor/scatter
factor (HGF/SF), and multi-drug resistance. Remarkably, we found that
all of these inducers have a common dominator; the ability to induce
H19 gene expression.
3.1.1. TGF-β induces H19 expression and miR-675 level through the
PI3K–AKT pathway
To test the effect of TGF-β on H19 expression, we treated human he-
patocellular carcinoma Hep3B cells with 2 ng/ml TGF-β for 48 h. As
shown in Fig. 1A (ﬁrst panel) and B, TGF-β treatment resulted in a
signiﬁcant induction of H19 RNA. To conﬁrm that TGF-β treatment
of Hep3B cells induces EMT, we checked for modulation of
established EMT markers. Transcription factors of the Snail family, in-
cluding Snail and Slug, are key inducers of EMT [19]. These two transcrip-
tion repressors are the most widely studied effectors of EMT and are
situated at the core of several signaling pathways. As shown in Fig. 1A
(second panel) & 1C, TGF-β treatment resulted in an up-regulation ofFig. 1. TGF-β induction of Slug, H19 andmiR-675 expressionswas dependent on the PI3K/AKT p
quantitative RT-PCR analyses. The integrity of the RT-PCR analyses was veriﬁed by analyzing β
TGF-β treatment was dependent on the PI3K/–AKT pathway as determined by QPCR analyses.
with an approximate 10 fold difference in h19 RNA level being higher in mesenchymal cells (×the expression levels of both EMT markers. H19 gene function could be
mediated by miR-675 processed from H19 exon 1. To check if TGF-β
also affects miR-675 levels, we quantiﬁed miR-675 before and after
TGF-β treatment. As shown in (Fig. 1D), TGF-β signiﬁcantly induced
miR-675 level along with H19 induction (p b 0.01).
We sought to identify the signaling pathway mediating the up-
regulation of both H19 and miR-675 in response to TGF-β treatment.
As TGF-β iswell known as a promoter of EMT, the phosphatidylinositide
3-kinase PI3K/AKT axis is emerging as a central feature of EMT. En-
hanced TGF-β receptor signaling was reported to maintain hyperactive
PI3K/AKT signaling, which in turn promoted EMT [20].
The effect of LY294002, a highly selective inhibitor of PI3K [21] on
EMT triggered by TGF-β treatment was investigated. Suppression of
the PI3K/AKT pathway before TGF-β treatment resulted in a signiﬁcant
decrease in the level of the EMT marker Slug to below that of non-
stimulated cells (Fig. 1C; p b 0.01). This indicates that TGF-β induction
of Slug in Hep3B cells is dependent on the PI3K/AKT pathway. To test
if TGF-β induction of H19 expression and miR-675 levels involves
the PI3K/AKT pathway, we investigated their modulation. While H19
was induced by TGF-β treatment in Hep3B cells, this induction was
abolished through pre-treatment of the cells with LY294002 prior to
TGF-β manipulation (Fig. 1B; p b 0.01) and miR-675 was also not in-
duced (Fig. 1D; p b 0.01). These results mechanistically link the induc-
tion of both H19 RNA and miR-675 in response to the TGF-β induced
EMT program to the PI3K/AKT pathway.
We further explored the effect of TGF-β on H19 expression using a
well-characterized mice cell line model of mammary carcinogenesis
that depends on the collaboration of the Ha-Ras oncoprotein and TGF-
β. Ha-Ras-transformed EpH4 mammary epithelial cells give rise toathway. (A) TGF-β induced H19 and Snail expressions inHep3B cells as analyzed by semi-
-actin expression. (B &C &D) The up-regulation of H19, Slug and miR-675 expressions by
(E) In a mouse model of mammary carcinogenesis, EMT induced by TGF-βwas associated
T) relative to epithelial cells (EPRAS) as determined by QPCR analyses. **P b 0.01.
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EMT in response to TGF-β both in vitro and in vivo giving rise to the
mesenchyme-like EpRas × T cells. We investigated whether H19 is
differentially expressed in EpRas and EpRas × T cells. As shown by
QPCR analysis, the H19 level was signiﬁcantly higher in mesenchyme-
like EpRas × T cells than in the epithelial EpRas cells (Fig. 1E; p b 0.01).
3.1.2. EMT induced by hypoxia is associated with a strong induction of both
H19 RNA and miR-675
We sought to determine whether hypoxia induced EMT is also
accompanied by the modulation of H19 gene expression and miR-675
levels.We used theMDA-MB- 468 breast cancer cell line that undergoes
EMTwhen cultured in hypoxic conditions [23]. MDA-MB- 468 cells cul-
tured in hypoxic conditions demonstrated an approximately 100-fold
increase in H19 mRNA compared with cells that were maintained
in normoxic conditions as quantiﬁed by QPCR analyses (Fig. 2A;
p b 0.01). To test if EMT markers are also inﬂuenced by hypoxia, we
analyzed Snail and Slug expression levels. As shown in Fig. 2B & C,
hypoxic treatment signiﬁcantly induced both of these EMTmarkers
(p b 0.05). Hypoxia also increased miR-675 levels along with the H19
induction (Fig. 2D;p b 0.01). These results demonstrate that hypoxia
induced EMT was associated with profound inductions of H19 RNA
expression and increased miR-675 levels.
3.1.3. Acquisition of chemo-resistance and EMT phenotype is associated
with an induction of H19 RNA in ovarian carcinoma cells
Increasing evidences suggest that EMT is important for the acquisi-
tion of a drug resistant phenotype in various types of human cancers
[24]. EMT gene signatures correlatewith the presence of drug resistance
[25]. The well characterized cisplatinum resistant ovarian adenocarci-
noma model (A2780cis), which has both the morphological and theFig. 2.Human breast carcinoma cells triggered to undergo EMTbyhypoxiamanifested a profoun
carcinoma cells (MDA-MB-468) were cultured in normoxic conditions or in 1.2% O2 hypoxic co
an approximate 100 fold induction by hypoxia. (B & C) Snail and Slug EMTmarkers showed hig
*P b 0.05.phenotypic hallmarks of EMT [26] represents a good model to test for
differential expression of H19 RNA compared to its epithelial parental
line (A2780). We examined the morphological characteristics of these
cell lines during exponential growth. In accordance with previous
work (Haslehurst et al. 2012), we demonstrated features of a mesen-
chymal phenotype in the resistant cells (Fig. 3A & B). H19 RNA was
induced approximately 20-fold in the chemo-resistant cell line with
the mesenchymal phenotype (Fig. 3C; p b 0.01). This correlated
with an increase in the expression level of the EMT transcription factor
Slug whichwas also induced 12-fold in the chemo-resistant mesenchy-
mal cells (Fig. 3D; p b 0.01).
3.2. H19 gene is highly expressed in common metastatic sites regardless of
tumor primary origin and its expression level signiﬁcantly correlates with
the metastatic potential of breast cancer cells
We compared the expression levels of the H19 gene in common
metastatic sites in selected biopsies of different tumor primary origin.
A set of slides from biopsies of ﬁve patients (Fig. 4.1–4.5) with metasta-
ses to lung (n = 2), brain (n = 1), liver (n = 1) and bone (n = 1), to-
gether with the primary tumors when available for the same patient,
were subjected to in situ hybridization (ISH). High H19 RNA expression
was detected in all metastatic sites tested, sometimes with higher ex-
pression levels relative to the tumor primary sites. In the case of serious
endometrial carcinoma and its lung metastasis (Fig. 4.2A & B) H19 ex-
pression was higher in the metastatic sites. H19 expression was similar
in peripheral cholagiocarcinoma and its lung metastasis (Fig. 4.1A & B)
and that of duct carcinoma of the breast and its brain metastasis
(Fig. 4.3A & B). H19 RNA was strongly expressed in liver metastasis of
colon carcinoma (Fig. 4.4) consistent with a previous report [27]. We
also observed strong H19 RNA expression in bone metastasis of breastd up-regulation of bothH19RNA andmiR-675 alongwith EMTmarkers. The humanbreast
nditions for 48 h before RNA extraction. Shown are (A) QPCR analyses for H19 RNA with
her expression level in hypoxia. (D)miR-675was also induced by hypoxic EMT. **P b 0.01,
Fig. 3. The cisplatinum resistant ovarian cancer cells (A2780cis) exhibitedmesenchymal phenotypes associatedwith an increase in the expression levels of bothH19 and Slug. (A & B) The
parental A2780 ovarian carcinoma cells, and its cisplatinum resistant variant visualized under 20× magniﬁcation showed different morphology. The drug resistant variant (B) have
morphological features of mesenchymal cells with more ﬁbroblastic appearance and demonstrate reduced intercellular contacts. These cells showed signiﬁcantly higher levels of both
H19 (C) and Slug (D) expressions as tested by QPCR analyses. **P b 0.01.
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mon metastatic sites examined regardless of the tumor primary origin.
Several syngeneic tumor lines with a spectrum of metastatic pheno-
types have been isolated from a spontaneous mammary tumor in
a BALB/cfC3H mouse [28]. The tumor lines were categorized as non-
metastatic (67NR), weakly metastatic to lymph node (168FARN)
or lung (66 cl4), or highly metastatic to lymph node, lung, and bone
(4 T1). This model has been extensively used to search for key regula-
tors of the metastasis cascade [29]. We sought to determine if the h19
gene is differentially expressed in these sub-lines with different meta-
static potential. RT-QPCR analyses revealed that h19 is highly expressed
in the 4 T1 cell line in comparison to the other lines which had no to
moderate h19 expression. Notably, an approximate 250-fold difference
in the expression level of h19 was noted between the non-metastatic
67NR cells and the highly metastatic 4 T1 cells (Fig. 5; p b 0.01). Fur-
thermore the expression level of h19 was signiﬁcantly higher in the
168FARN cell line (weakly metastatic to lymph node; p b 0.01) and in
the 66 cl4 cell line (weakly metastatic to lung; p b 0.01).
3.3. Evidence supporting the existence of a Slug-H19 positive loopmediated
through miR-675 involved in the suppression of the epithelial marker
E-cadherin
We hypothesized that transcription factors that regulate EMT can
modulate H19 RNA expression. Slug is a mediator of EMT and tumor
metastasis. We utilized the ovarian carcinoma A2780 parental line as a
model and transiently transfected it with a plasmid vector that drives
the expression of Slug under the control of the (CMV) promoter after
sub cloning it into the backbone pCMV-Skript vector [30 and material
and methods]. As shown in Fig. 6A, Slug signiﬁcantly up-regulated the
expression level of H19 RNA (p b 0.01).
Since it is a transcription factor, we hypothesized that Slug may
up-regulate H19 expression by enhancing its transcription. To checkthis possibility, we cloned an approximately 0.8 Kbp H19 promoter
upstream of a luciferase reporter. We then co-transfected the H19
promoter with the Slug expressing plasmid, or the H19 promoter with
an empty inert vector into the A2780 ovarian carcinoma cell line. As
shown in Fig. 6B, Slug signiﬁcantly up-regulated H19 promoter activity
about 3-fold (p b 0.01). To check if this effect was a general one, we co-
transfected Slug expressing vector with the Luc-4 vector which drives
the expression of luciferase under the control of the SV40 promoter.
Co-transfection with Slug did not modulate the activity of the SV40
promoter as shown in Fig. 6B. Bioinformatic analysis revealed that the
0.8 Kbp promoter of H19 does not contain a Slug binding site (data
not shown), suggesting that this effect may be indirect.
In order to determine if H19 could modulate Slug expression, we
chose the pancreatic cancer cell line Panc-1, since it has a low Slug
expression (Fig. 6C) and we were searching for inducers. Ectopic ex-
pression of H19 RNA using the vector that drives the expression of
H19 gene under the control of the CMV promoter, although resulted
in mild up-regulation of H19 RNA (1.8-fold; data not shown), highly in-
duced Slug expression (Fig. 6C), but did not induce Snail expression
(Fig. 6D). The enhancement was abrogated when an H19 expression
plasmid mutated in the seed region of miR-675 was used (Fig. 6C). In-
terestingly, this was accompanied by suppression of the Slug target E-
cadherin in H19 over-expressing Panc-1 cells, but not in cells
transfected with the mutated miR-675 version of the plasmid
(Fig. 6F), indicating that this ﬁndingmay have functional consequences.
Altogether, these results indicate that H19 up-regulated Slug expression
and that this was dependent on intact miR-675 and resulted in the sup-
pression of the epithelial marker E-cadherin.
We then explored if TGF-β induced Slug up-regulation in Hep3B
cells is dependent on H19 RNA. We stably transfected Hep3B cells
with a plasmid expressing H19 shRNA, or a control shRNA. H19 shRNA
transfection resulted in very efﬁcient H19 knockdown (data not
shown). These cells were then stimulated to undergo EMT by TGF-β
Fig. 4. High H19 expression level presented in all common metastatic sites tested regardless of tumor primary origin. ISH results showed that H19 was expressed in all selected biopsies
derived from 5 patients (4.1–4.5) as representative samples for themost commonmetastatic sites. Primary tumors were also available for 3 patients (4.1A, 4.2A and 4.3A). The speciﬁca-
tions of each tumor type described under each part of the ﬁgure.
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induced by TGF-β as previously described but this is dependent on H19
RNA (Fig. 7A).Fig. 5. Highest h19 expression level was detected in cells with the highest metastatic potential
67NR cells and the highlymetastatic 4T1 cells was detected byQPCR analyses. Thiswidely recog
a spectrum of metastatic phenotype as described in the results section. **P b 0.01.We next showed using two H19 siRNAs targeting different re-
gions of H19 RNA that H19 enhanced the induction of Slug in re-
sponse to TGF-β treatment in bladder cancer UMUC3 cells. This. An approximate 250-fold difference in h19 expression level between the non-metastatic
nizedmice cell line variants isolated from a spontaneousmammary tumors known to have
Fig. 6. Evidence of a Slug-H19-miR675 positive feedback loop controlling E-cadherin expression. (A) The ovarian carcinoma cell line (A2780)was transfectedwith Slug expression vector
driven by CMVpromoter (CMV-Slug) or a control vector (CMV-Empty). Results showed an up-regulation of the expression level of H19 RNA by Slug as detected byQPCR analyses (B). Slug
enhancedH19 but not SV40 promoter activity asmeasured by co-transfection of Slug expression vector with either H19 or SV40 promoters that drived the expression of luciferase report-
er. (C) H19 induced Slug expression in Panc-1 cells was dependent on intact miR-675. Stable Panc-1 clones either over-expressing H19 RNA, H19 RNA with miR-675mutated in seed re-
gion , and a control vector (CMV promoter with empty insert) were generated and Slug expression level was checked by RT-PCR analyses (D) RT-PCR analyses for Snail showing
no modulation. (E) RT-PCR analyses for GAPDH to test for RT-PCR integrity. (F) Western blot analyses of E-cadherin protein showing that the consequent up-regulation of Slug by H19
with an intact miR-675 may be reﬂected by the complete abolishment of E-cadherin protein level. **P b 0.01.
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Treatment of UMUC3 cells with TGF-β signiﬁcantly induced Slug ex-
pression of about seven fold (p b 0.01). Both H19 siRNAs resulted in
very efﬁcient H19 knockdown (data not shown). Knockdown of H19
RNA prior to TGF-β treatment signiﬁcantly attenuated Slug induction
(Fig. 7B; p b 0.05).
We then investigated the involvement of H19 RNA in the suppres-
sion of E-cadherin in two other cancer cell lines of different origin—
Hep3B cells (hepatocellular carcinoma) and H358 cells (lung carcino-
ma). Clones of these cells ectopically over expressing H19 under the
control of the CMV promoter were generated. We veriﬁed very high
H19 up-regulation by RT-PCR analyses (data not shown). Western blot
analyses revealed that H19 over-expression resulted in no detectable
level of E-cadherin protein in both cell lines (Fig. 7D) and an up-
regulation of N-cadherin in H358 cells (Fig. 7C).
3.4. H19 enhances migratory potential of cells in vitro and enhances tumor
metastasis in vivo
In light of our ﬁndings,we decided to functionally assess the effect of
H19 RNA over-expression on the invasive ability of cancer cells in vitro
and the metastasizing ability in vivo. Forced expression of H19 gene in
the non-invasive Hep3B cells enhanced in vitro cell invasion of
about two fold as quantiﬁed by Image Pro-Plus (data not shown)
compared with the control cells which contained an empty vector.This can be seen as an increase in the intensity of the blue color of
the Giemza stain (Fig. 8A & B), which stains cells that successfully in-
vade an artiﬁcial membrane. Shown are representative samples.
In vivometastasis assays were performed to ascertain whether H19
RNAhas a role in themetastatic behavior of lung cancer cells. Forced ex-
pression of H19 RNA in H358 cells enhanced their capacity to generate
lung metastases after being injected intravenously into the tails of
athymic mice. H358 control cells (stably transfected by an empty vec-
tor) and H358-CMV-H19 cells (ectopically expressing H19 under the
transcriptional control of CMV promoter) were injected into the tail
vein. 28 days post-injection, 33% of the mice injected with H358-CMV-
H19 cells (n = 6) had visible metastasis in their lungs while none of
themice injectedwith theH358 control cells (n=6) had visiblemetas-
tasis in any organ.
Histological analyses of the lungs of the injected mice showed that
themajority (5/6) of themice injectedwith H358-CMV-H19 had devel-
oped several micro-metastatic foci in many locations in the lung com-
pared to 3/6 mice that had developed fewer micro-metastasis foci of
smaller size in the H358 control cell group. Representative histology
for both groups of mice is shown in Fig. 8C & D.
Altogether, our in vitro and in vivo functional analyses suggest that
H19 RNA expression in hepatocelluar and lung carcinomas plays an im-
portant role in enhancing the invasive potential of the cells for the
former and in the acquisition of high metastatic potential of the cells
for the later.
Fig. 7. Knock-down of H19 attenuated Slug induction in response to TGF-β, whereas H19 RNA over expression abolished the epithelial marker E-cadherin protein level. Stable clones of
Hep3B cells either transfected with H19 shRNA or negative control shRNA were generated. TGF-β treatment resulted in the induction of Slug expression that depended on H19 RNA.
Shown (A) RT-QPCR analyses for Slug.(B) To verify that Slug attenuation is not attributed to H19 shRNA off-target effect, and to broaden this observation, we transiently knocked
down H19 RNA in bladder carcinoma UMUC3 cell line by two different H19 siRNAs prior to TGF-β stimulation. Again Slug induction by TGF-β depended on H19 RNA as quantiﬁed by
QPCR analyses. **P b 0.01, *P,0.05. In addition stable clones of hepatocellular carcinoma (Hep3B) cells and lung carcinoma (H358) cells over-expressingH19were generated and subjected
towestern blot analyses for N-cadherin (C), E-cadherin (D), and GAPDH (E). E-cadherin protein levelswere reduced to zero by H19 in both cell lines tested (D) andwas associatedwith an
up-regulation of mesenchymal marker N-cadherin in H358 cells (C). To test for western blot integrity GAPDH protein level was examined (E).
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SF in lung carcinoma cells and ablates HGF/SF tumorigenic enhancing
property
We decided to explore the HGF–H19 relationship in lung cancer cell
lines. The A549 and H358 cell lines have been reported to express the
tyrosine kinase c-Met receptor [31]. When HGF was added at differ-
ent concentrations to the medium, the luciferase gene product
expressed under the transcriptional control of 0.8 kb H19 promoter
was up-regulated both in normal and hypoxic cell culture conditions.
The H19 promoter was unresponsive to hypoxic stress (Fig. 9A & B).
These results are in accordance with a previous study [32].
We present here new evidence showing that the tumorigenic and
scattering effect of HGF/SF on the A549 cells can be attenuated by
H19 knockdown. HGF/SF treatment resulted in enhancement of
in vitro tumorigenicity measured by anchorage independent growth
through increasing in the number of colonies grown on soft agar in
both normoxic and hypoxia recovery conditions (Fig. 9C). In hypoxia
recovery conditions cells were ﬁrst exposed to transient hypoxic
stress for 24 h then seeded on soft agar with or without HGF/SF treat-
ment. HGF/SF treatment had a more pronounced effect on increasing
colony numbers after hypoxia recovery (Fig. 9C).
The experiment was repeated in cells whose H19 expression had
been successfully silenced using H19 siRNA (data not shown). Theability of these H19 knockdown cells to form colonies on soft agar
was attenuated (Fig. 9C), consistent with the known oncogenic func-
tion of H19 RNA [6]. Moreover, H19 knockdown attenuated the abil-
ity of HGF/SF to induce colony formation. The number of colonies
formed when cells were transfected with H19 siRNA was signiﬁcant-
ly less compared to two control groups transfected with siRNA
targeting luciferase (si-LUC) and mock transfection (Pb0.01). Fur-
thermore, the scattering morphology of the clones induced by HGF/
SF was totally dependent on H19 RNA (Fig. 9D). Altogether these re-
sults show that in vitro tumoriginicity and the scatering phenotype
induced by HGF/SF depend at least in part on H19 RNA. Similar re-
sults were obtained in H358 cells using a different H19 siRNA, indi-
cating that the results were speciﬁc and not due to an off-target
effect of H19 siRNA (data not shown).
4. Discussion
During tumor progression, malignant tumors can be reprogrammed
intomesenchymal like cells through the process of EMT. This conversion
explains how epithelial tumor cells escape their primary sites to form
distinct metastasis, the fatal outcome of most cancer types. Recent data
even link EMT to cancer stem cells and drug resistance (for review see
[24]). So understanding the molecular circuits driving this conver-
sion is vitally important. In the present study, we have provided
Fig. 8.H19 enhanced the invasive potential of Hep3B cells in vitro and themetastatic potential of H358 cells in vivo. Representative samples for in vitro invasion assay for thenon-metastatic
Hep3B cells (A), compared to the same cell line over-expressing H19 RNA (B). The intensity of the blue dye (Giemsa stain), was directly proportional to the number of cells invading an
artiﬁcial membrane. Results showed that H19 RNA enhanced the invading potential of Hep3B cells in vitro. Representative samples of the lung tissues of mice intravenously injectedwith
H358 lung carcinoma cells (C) and H358 cells over-expressing H19 RNA (D). Results showed small microscopic tumor foci detected after 28 days post injection of H358 parental cells in
some of the injectedmice lungs. H358 cells over-expressing H19 RNA formed tumors in themajority of themice lungs, sometimes visible to naked eyes with largemicroscopic tumor foci.
Results showed that H19 RNA enhanced H358 tumor metastasis in vivo.
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the H19/miR-675 in promoting metastasis at least in part by being in-
volved in the EMT process.
Although it was discovered nearly thirty years ago [33], key ques-
tions regarding H19 gene properties, function and mechanism of action
remain to be resolved. Several lines of evidence supporting the involve-
ment of H19 RNA in the metastatic cascade have accumulated over the
past few years. Previous reports including those of our own group have
identiﬁed H19 RNA as one of the genes that is up-regulated by hypoxic
stress [6,13], and in response to HGF/SF [32], two of thewell established
inducers ofmetastasis. Disease-free survival from theﬁrst biopsy to ﬁrst
recurrence was signiﬁcantly shorter in patients with tumors having a
larger fraction of H19 expressing cells [34]. Furthermore we identiﬁed
H19 downstream targets [6,15] that showed a clear preference towards
genes promoting cellular migration, angiogenesis and metastasis. All of
these observations and others are in accordance with the idea that the
H19 gene may have a role in promoting tumor metastasis, however,
the pro-oncogenic events capable of regulating H19 RNA remain largely
uncharacterized and furthermore both functional and mechanistic data
are absent.
In this study we explored H19's role in the metastatic cascade. As a
ﬁrst step to establishing this role, we showed that H19 is expressed in
all metastatic sites examined irrespective of tumor primary origin that
may indicate that H19 activation is a general phenomenon of themeta-
static event.
Moreover in a mouse mammary cancer cell line model we showed
that H19 expression matched metastatic potential. Interestingly,
similar results have been obtained by Yang et al. [29, supplementary
information], on their study on the importance of Twist as a regulator of
EMT. Bymicroarray analyses they have looked at candidate genes regu-
lating this phenotype and found that themost up-regulated gene is H19
RNA, just above Twist itself.Among the extracellular factors that activate the EMT program, TGF-
β, hypoxia, and HGF/SF represent potent EMT inducers. Moreover, the
EMT program is linked to multidrug resistance. TGF-βmediates several
and sometimes opposite effects on epithelial cells. It can induce both
pro- and anti-apoptotic signals in human fetal hepatocytes, and also
can induce and maintain EMT [35]. Furthermore evidence provided by
numerous studies suggests that hypoxic conditions “per se” can trigger,
as an independent factor, an EMT program leading different types of
human cancer cells to signiﬁcantly increase invasiveness. HIF-1-
regulated genes promote angiogenesis, invasion and EMT, a critical
step of metastasis [36].
Interestingly, all EMT master inducers tested in our study induced
H19 RNA (also miR-675 when tested) along with EMT markers.
This mechanistically put H19/miR-675 in the core of the EMT pro-
cess through multiple signaling pathway. One pathway identiﬁed in
this study is the PI3K–AKT pathway.
A pivotal hallmark of EMT is the loss of E-cadherin expression,which
is consistently observed at sites of EMT during development and cancer
and which is involved in the transition of adenoma to carcinoma in
animal models [37]. Our results show that H19 RNA over-expression
abolishes E-cadherin protein, and is sometimes associated with an
increase of N-cadherin protein. This effect is miR-675 dependent and
associated with Slug but not Snail up-regulation.
These results suggest that H19 may suppress E-cadherin expres-
sion by up-regulating Slug, via a mechanism that involves miR-675.
The exact sequence of events and miR-675 targets require further
investigation.
Our results also demonstrate that Slug can up-regulate H19 expres-
sion and activate its promoter possibly through an indirect mechanism.
Altogether, this may support the existence of a positive feedback
loop between H19 and Slug mediated by miR-675 which controls
E-cadherin expression. Further investigation is needed to identify
Fig. 9. H19 knockdown abolished the scattering effect of HGF/SF, and attenuated colony formation and induction on soft agar. (A & B) A549 and H358 cells (left and right, respectively)
were seeded in 12-well plates and transfected with plasmid expressing the luciferase gene under the control of the H19 gene promoter. 24 h post transfection medium was removed
and newmedium containing 20 or 40 ng/ml of HGF/SF was added to A549 and H358 respecyively. HGF/SF induced H19 promoter activity in both cell lines, in normoxic and hypoxic con-
ditions. (C &D)A549 cells were seeded and next day cells were transfectedwith 250 pmol of siRNA, in duplicates, targeting the luciferace (siLUC) or theH19 RNA (siH19-1) or left to grow
with no treatment (N.T.). 12 h post transfection the medium was renewed and one dish from each duplicate was transferred to hypoxic growth conditions for 24 h while the other dish
remained in normal conditions. After 24 h, 5000 cells fromeachgroupwere seeded in soft agar in sixwells dish. Two triplicates of 6-well disheswere seeded (total of six dishes) and for the
next 4 weeks cells were left to grow under normal growth conditions. Mediumwas renewed every 3–4 days and for one of the two triplicate HGFwas added in concentration of 20 ng/ml
every time upon medium removal. (A) The number of colonies formed in the soft agar for each one of the growth conditions was determined under a light microscope, as described in
material & methods. Colonies were dyed using crystal violet 0.05%, counted and photographed under the light microscope.
Fig. 10. Schematic representation of the hypothesized role of H19/miR675 in the EMTpro-
cess. Various EMT inducers through multiple signaling pathways (e.g. TGF-β through
PI3K–AKT pathway) converge to H19/miR675 to up-regulate their levels. These inducers
also up-regulate Slug and resulted in suppression of E-cadherin. The mediator of this
step is H19/miR675 in a positive feedback loop with Slug through which miR-675 targets
an unknown inhibitor for Slug leading to Slug up-regulation, which in turn enhances
H19/miR675 levels. This positive feedback loop could account for the induction and
maintenance of the mesenchymal phenotype besides explaining the tumorigenic activity
of EMT inducers which is largely uncharacterized.
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this target could be a natural inhibitor of Slug expression, and that
this positive feedback loop could be responsible for inducing and
then maintaining the mesenchymal phenotype of tumor cells. This
hypothesis is presented in Fig. 10.
Our in vitro and in vivo functional studies indicate that H19 is
involved in enhancing invasion and metastasis and also mediates the
tumorigenic and scattering phenotypes induced by HGF/SF.
During the writing of this report, two conﬂicting studies linked H19
to the metastatic cascade [38,39]. H19 enhanced the metastatic
potential of bladder cancer cells [38], while suppressed that of the
hepatocellular carcinoma, being involved in the mesenchymal to
epithelial transition (MET) [39]. However, MET is an integral part
of the metastatic cascade that participates in the establishment and
stabilization of distant metastases by allowing cancerous cells to re-
gain epithelial properties and integrate into distant organs [40]. H19,
thus, could be involved in both EMT and MET.
H19 RNA is one of themost highly expressed genes in embryogene-
sis and placental development. After birth, it is shut down in most tis-
sues, but reactivated in cancers. It is also reactivated in certain
physiological and non-cancerous pathological conditions (for recent re-
view see [8]).
It is well established that numerous physiological processes involv-
ing cellular invasion, blastocyst implantation, placental development,
1425I.J. Matouk et al. / Biochimica et Biophysica Acta 1843 (2014) 1414–1426tissue repair and remodeling, wound healing, and loss of pluripotency
all involve EMT. Interestingly these physiological processes are mani-
fested by high levels of H19 RNA [41]. Moreover, aberrant EMT also
elicits disease development in humans, including rheumatoid arthritis
(RA) [42]. It was shown that the PI3K/AKT/HIF-1α pathway is associat-
ed with hypoxia-induced EMT in ﬁbroblast-like synoviocytes of RA. In-
terestingly, RA is nearly the only known non-cancerous pathological
process that is associated with activation of H19 RNA [43]. We hypoth-
esize that the mode of H19 gene expression in cancer and in speciﬁc
physiological and diseased non-cancerous states in adults, has seemingly
a common denominator in terms of the triggers and possibly the targets.
Activation of H19 by either oncogenic signals or non-cancerous patholog-
ical signals activates a common gene program that affects processes com-
mon to both events. However, a crucial difference is that in the case of a
normal physiological signal, H19 activation is transient, while H19 is per-
sistently activated in cancer.
Although further studies are required to comprehensively deﬁne
the role of H19 and its micro-RNA in the metastatic cascade, our re-
sults not only describe a novel player in the EMT process, but addi-
tionally demonstrate the broad range of functions of a lncRNA gene
once thought to be no more than a transcriptional noise. We have
provided one of relatively few examples in the ﬁeld of a critical role
played by a lncRNA gene in promoting cancer metastasis. While the
involvement of EMT inducers in the invasion-metastasis cascade of
epithelial tumors is well delineated, their contribution in tumorigen-
esis remains unclear. On the basis of our previous and current ﬁnd-
ings, we propose (and conﬁrm it in the case of HGF/SF) that H19
could be one of the central mediators through which those EMT in-
ducers contribute to tumorigenesis.
This further emphasizes the pathological roles played by lncRNA
genes and makes them targets in our ﬁght against cancer. Indeed both
pre-clinical and clinical studies of BC-819 (a plasmid comprised of the
H19 gene regulatory sequences that drive the expression of diphtheria
toxin A speciﬁcally in tumor cells expressingH19 RNA) showpromising
outcomes. BC-819-targeted therapy combined with gemcitabine totally
ablated metastasis in an aggressive orthotopic pancreatic carcinoma
model [44], while clinical trials showpromising results in various cancer
indications [8]. Our results highlight the importance of targeting H19
RNA, or cells expressing H19 RNA, for therapeutic interventions and
the prevention of tumor metastasis, the fatal outcome of all cancer
types.
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GAPDH glyceraldehyde 3-phosphate dehydrogenase
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HIF-1α hypoxia-inducible factors alpha
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